Graham Capital Management’s PTC Therapeutics PTCT Stock Holding History

Graham Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-26,061	Closed	-$1.27M	–	1568
2025 Q2	$1.27M	Buy	26,061 +9,336	+56%	+$443K	0.02%	504
2025 Q1	$852K	Buy	16,725 +1,727	+12%	+$86.2K	0.01%	603
2024 Q4	$677K	Buy	+14,998	New	+$642K	0.01%	625
2024 Q3	–	Sell	-17,366	Closed	-$531K	–	1292
2024 Q2	$531K	Buy	+17,366	New	+$563K	0.01%	568
2024 Q1	–	Sell	-13,023	Closed	-$359K	–	1263
2023 Q4	$359K	Buy	+13,023	New	+$298K	0.01%	680
2023 Q3	–	Sell	-15,103	Closed	-$614K	–	1237
2023 Q2	$614K	Buy	+15,103	New	+$739K	0.02%	500
2022 Q3	–	Sell	-54,001	Closed	-$2.16M	–	1268
2022 Q2	$2.16M	Buy	+54,001	New	+$1.89M	0.09%	187

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's PTCT Position: Q3 2025 in Review

Graham Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 26,061 shares — an estimated $1.27M sold.

Graham Capital Management first reported a position in PTCT in Q2 2022 and held it in 7 quarters. The position peaked at $2.16M in Q2 2022. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Graham Capital Management reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Graham Capital Management sold 26,061 PTC Therapeutics shares in Q3 2025, an estimated $1.27M.
Graham Capital Management first reported a position in PTC Therapeutics in Q2 2022 and held it in 7 quarters.
Graham Capital Management's PTC Therapeutics position peaked at $2.16M in Q2 2022.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.